US 11801234
Methods of treating APOL-1 dependent focal segmental glomerulosclerosis
granted A61KA61K31/404A61K31/4045
Quick answer
US patent 11801234 (Methods of treating APOL-1 dependent focal segmental glomerulosclerosis) held by Vertex Pharmaceuticals Incorporated expires Mon Oct 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Vertex Pharmaceuticals Incorporated
- Grant date
- Tue Oct 31 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Oct 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 38
- CPC classes
- A61K, A61K31/404, A61K31/4045, A61K31/573, A61K45/06